Video

Vibeke Strand, MD, on the Success of Secukinumab for Psoriatic Arthritis

Author(s):

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

In an interview with HCPLive®, Vibeke Strand, MD, MACR, FACP, Division of Immunology and Rheumatology, Stanford University, discussed her study on the effect of secukinumab in patients with active psoriatic arthritis (PsA).

The Phase 3 data displayed clinical and radiographical efficacy. Patients reported significantly sustained improvements across all dose levels compared with placebo.

This study included patients who were naive to tumor necrosis factor (TNF) inhibitor, as well as patients who were TNF-inadequate or TNF-incomplete responders.

Strand explained that patients who have been heavily treated, who are TNF-incomplete responders, might appear less improved because their scores were lower at baseline compared to patients who were TNF-naive. However, they actually reported very similar amounts of improvement.

"If you account for the fact that they're starting with lower scores because they've had the disease for longer, and they've had more failed treatments, what you can see is that actually, they're able to respond as well as a naive population," Strand said. "It's just that the baseline scores are lower."

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.